Use of a global assay of coagulation and fibrinolysis to aide in thromboembolism

Abstract

The present invention provides methods for identification of subjects with a rise in plasma coagulability post-diagnosis of thrombotic event (and consequent increased risk for recurrent thromboembolism) as well as for identification of subjects without thrombotic event who exhibit a rise in plasma coagulability for which prophylactic anticoagulation may be warranted for TE prevention, and other methods for identification of perioperative subjects who are at heightened risk for perioperative bleeding and/or for requiring blood transfusion, using the CloFAL assay, to aid in clinical decision making regarding anticoagulant and/or adjunctive clinical management designed to mitigate this heightened thromboembolic risk.

1 . A method for diagnosing risk of rise in plasma coagulability in a subject who previously experienced a thrombotic event (TE) and has undergone anticoagulation therapy, comprising the steps of:
 a) analyzing a first biological sample taken from a subject at time period of about 4 to about 6 weeks post-diagnosis of TE, using the CloFAL assay method and generating a CloFAL MA value;   b) analyzing a second biological sample taken from a subject at time period of about 3 months post-diagnosis of TE using the CloFAL assay method and generating a CloFAL MA value;   c) comparing the CloFAL maximum amplitude value of a) to b); and   d) identifying the subject as being at risk for a rise in plasma coagulability when the CloFAL MA value of b) is at least 50% greater than the CloFAL MA value of a).   
     
     
         2 . The method of  claim 1 , wherein the second biological sample is taken from a subject at time period of about 6 months post-diagnosis of TE. 
     
     
         3 . The method of  claim 1 , wherein the second biological sample is taken from a subject at time period of greater than 6 months post-diagnosis of TE. 
     
     
         4 . The method of  claim 1 , wherein the biological sample is a blood sample. 
     
     
         5 .- 8 . (canceled) 
     
     
         9 . A method for identification or diagnosis of who is at risk for a marked rise in plasma coagulability and recurrent thromboembolism in a subject who previously experienced a thrombotic event (TE) and underwent coagulation therapy comprising the steps of: a) analyzing a first biological sample taken from a subject at time period of about 6 weeks+/−2 weeks prior to planned cessation of coagulation therapy using the CloFAL method and generating a CloFAL maximum amplitude value; b) analyzing a second biological sample taken from a subject at time of planned cessation (or within about 2 weeks post-cessation) of anticoagulation therapy using the CloFAL method and generating a CloFAL maximum amplitude value; c) comparing the CloFAL maximum amplitude value of a) to b); and d) identifying the subject as having a marked rise in plasma coagulability and therefore as being at heightened risk for recurrent thromboembolism when the CloFAL maximum amplitude value of b) is at least 50% greater than the CloFAL maximum amplitude value of a). 
     
     
         10 . The method of  claim 9 , wherein the second biological sample is taken from a subject at time period of about is at least about 1 month to about 24 months post-cessation of coagulation therapy. 
     
     
         11 . The method of  claim 10 , wherein the second biological sample is taken from a subject at time period at least about 3 months post-cessation of coagulation therapy. 
     
     
         12 . The method of  claim 9 , wherein the biological sample is a blood sample. 
     
     
         13 .- 15 . (canceled)